Multi-functional particles for near-infrared imaging guidance and photothermal therapy and composite comprising same
Multifunctional particles with a core-shell structure and tumor-targeting antibodies enhance near-infrared imaging and photothermal therapy efficiency, addressing low photothermal efficiency and interference issues, achieving high cancer cell killing rates and improved imaging accuracy.
Patent Information
- Application Number
- PCT/KR2024/006116
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-02
- Filing Date
- 2024-05-08
- Publication Date
- 2024-11-21
Smart Images

Figure KR2024006116_21112024_PF_FP_ABST
Abstract
Description
Multifunctional particles for near-infrared imaging-guided and photothermal therapy and composites containing the same
[0001] The present invention relates to materials, and more particularly, to multifunctional particles for near-infrared imaging guidance and photothermal therapy, and a composite comprising the same.
[0002] Bioimaging is a technology that utilizes image analysis equipment to observe living organisms or cells in real time or to confirm results through images. Optical imaging, a type of imaging technology, utilizes light to visualize target tissues and organs. Optical imaging probes that provide image signals through direct or indirect interactions with in vivo or ex vivo targets are being steadily developed.
[0003] Specifically, near-infrared imaging is currently attracting attention in the field of optical imaging due to its deep penetration capability, low phototoxicity, and minimal interference from tissue autofluorescence. In particular, upconversion nanomaterials, which absorb low-energy photons and emit high-energy photons, possess properties suitable for near-infrared imaging and are expected to play a key role as bioimaging probes in diverse fields, including biomedicine, energy, and catalysis research.
[0004] Meanwhile, NaNdF4, LaF3:Nd as new multifunctional nanoparticles (NPs) for photothermal therapy 3+Neodymium (Nd)-doped nanoparticles, such as NdVO4 materials, have been introduced. However, neodymium (Nd)-doped nanomaterials have low absorption coefficients and photothermal efficiencies, making it difficult to achieve the critical temperature for thermal ablation of tumors. To address this issue, methods of adding heterogeneous materials, such as Prussian blue, copper sulfate (CuS), manganese dioxide (MnO2), or carbon (C), to multifunctional particles have been proposed. However, the addition of heterogeneous materials can negatively affect optical properties, such as absorption capacity or luminescence efficiency.
[0005] In addition, real-time imaging-guided PTT has the advantages of minimal invasiveness and convenience of on-site operation, but conventional intensity-based imaging signal measurement has problems with luminescence signal disturbance due to penetration depth, laser-induced autofluorescence, and background interference.
[0006] Accordingly, the technical problem to be solved by the present invention is to provide a multifunctional particle for near-infrared imaging-induced photothermal therapy and a complex including the same, which can improve the performance of photothermal therapy.
[0007] In addition, the technical problem to be solved by the present invention is to provide a multifunctional particle for near-infrared imaging and photothermal therapy and a complex including the same, which can solve the problem of performance degradation of a bioimaging probe due to a biological luminescence signal causing disturbance.
[0008] The technical problems of the present invention are not limited to the technical problems mentioned above, and other technical problems not mentioned will be clearly understood by those skilled in the art from the description below.
[0009] In order to achieve the above task, one aspect of the present invention provides a multifunctional particle comprising a core that absorbs light having a first wavelength and emits near-infrared light having a second wavelength shorter than the first wavelength while inducing near-infrared imaging, and a shell located outside the core that absorbs light having a third wavelength and emits light having a fourth wavelength that induces absorption of water while locally heating water molecules.
[0010] The light having the first wavelength and the light having the third wavelength are both near-infrared, but may have different wavelength ranges.
[0011] The range of the first wavelength may be 950 to 980 nm, and the range of the second wavelength may be 800 to 850 nm.
[0012] The range of the fourth wavelength may be 950 to 1,050 nm.
[0013] The range of the third wavelength may be 780 to 808 nm.
[0014] The light having the first wavelength can be supplied using a pulse laser.
[0015] The near-infrared light having the second wavelength may have a lifetime in the range of 300 to 600 microseconds (μs).
[0016] The core and the shell comprise the same host material, and the core and the shell may have dopants of different compositions.
[0017] The core comprises at least one host material selected from the group consisting of NaYF4, NaGdF4, KGdF4, YOF, BaLaF5, LaF3, NaLuF4, and SrF2, wherein the host material comprises Yb 3+ , Tm 3+ , Er 3+ , Eu 3+ and Pr 3+ At least one of the dopants may be doped.
[0018] The core comprises a host material composed of NaYF4, wherein the host material comprises Yb 3+ Wow Tm 3+ These can be doped at the same time.
[0019] The core comprises Na(a mol% Y)F4:b mol% Yb, c mol% Tm, wherein a is 100-bc, b is 40 to 60, and c is 1 to 10.
[0020] The above shell comprises at least one host material selected from the group consisting of NaYF4, NaGdF4, KGdF4, YOF, BaLaF5, LaF3, NaLuF4, and SrF2, wherein the host material comprises Yb 3+ , Ln 3+ , Nd 3+ , Sm 3+ , Dy 3+ and Ho 3+ At least one dopant may be doped among them.
[0021] The above shell comprises a host material composed of NaYF4, wherein the host material comprises Yb 3+ Wow Nd 3+ These can be doped at the same time.
[0022] The above shell comprises Na(x mol% Y)F4:y mol% Nd, z mol% Yb, wherein x is 100-yz, y is 20 to 70, and z can be 10 to 30.
[0023] The photothermal conversion efficiency of the above multifunctional particles may be 8 to 23%.
[0024] Another aspect of the present invention provides a complex comprising a multifunctional particle comprising a core that absorbs light having a first wavelength and emits near-infrared light having a second wavelength shorter than the first wavelength, thereby inducing near-infrared imaging, and a shell located outside the core that absorbs light having a third wavelength and emits light having a fourth wavelength that induces absorption of water, thereby locally heating water molecules, and a tumor-targeting antibody attached to the surface of the multifunctional particle.
[0025] The above tumor-targeting antibody specifically binds to cancer cells, and the multifunctional particle can kill the cancer cells by locally heating water molecules.
[0026] The cancer cells may be at least one cell selected from glioblastoma cells, sarcoma cells, lymphoma cells, glioma cells, breast cancer cells, head and neck cancer cells, prostate cancer cells, and lung cancer cells.
[0027] The multifunctional particles for near-infrared imaging-induced and photothermal therapy of the present invention emit light of a near-infrared wavelength with a long lifetime of several microseconds, thereby facilitating near-infrared imaging-induced and enabling independent detection of signals.
[0028] In addition, the multifunctional particles for near-infrared imaging-induced and photothermal therapy of the present invention can emit light of a wavelength at which strong absorption of water molecules occurs with the strongest luminescence intensity, thereby realizing a photothermal effect of 23% or more.
[0029] In addition, by using the complex of the present invention, which combines the near-infrared imaging-induced multifunctional particle for photothermal therapy and the antibody targeting the tumor, more than 78% of cancer cells can be killed during tumor treatment.
[0030] Accordingly, the multifunctional particles for near-infrared imaging and photothermal therapy of the present invention and the complex containing the same can be actively utilized for imaging and photothermal ablation in the treatment of various tumors and cancer cells.
[0031] The technical effects of the present invention are not limited to those mentioned above, and other technical effects not mentioned will be clearly understood by those skilled in the art from the description below.
[0032] Figure 1 is a schematic diagram showing a multifunctional particle for near-infrared imaging guidance and photothermal therapy according to one embodiment of the present invention.
[0033] FIG. 2 is a schematic diagram of inducing near-infrared (NIR) imaging using a pulse laser in a multifunctional particle according to one embodiment of the present invention.
[0034] FIG. 3 is a schematic diagram showing a photothermal treatment performed by irradiating a continuous wave laser (CW laser) on a multifunctional particle according to one embodiment of the present invention to locally heat water molecules, and an energy band diagram of the multifunctional particle related thereto.
[0035] FIG. 4 is a schematic diagram showing a multifunctional particle for near-infrared imaging and photothermal therapy doped with ytterbium (Y), tholium (Tm), and neodymium (Nd) according to one embodiment of the present invention.
[0036] Figure 5 is a schematic diagram showing the thermal effect induced by cross relaxation (CR) of the particles of Comparative Example 1 and the multifunctional particles of Manufacturing Example 1.
[0037] Figure 6 is a schematic diagram showing the photothermal effect of the multifunctional particles of Manufacturing Example 1 of the present invention.
[0038] Figure 7 shows the multifunctional particles of Manufacturing Example 1 of the present invention at 0.1 W / cm 2This is a graph comparing the 1.0㎛ emission spectra in cyclohexane and aqueous solution, respectively, by power density, and the image is an optical image of the multifunctional particles of Manufacturing Example 1 in cyclohexane and aqueous solution.
[0039] FIG. 8 is a graph showing the near-infrared (NIR) absorbance spectrum of cyclohexane and water according to one embodiment of the present invention.
[0040] Figure 9 shows the cyclohexane (0.5 W / cm) of the present invention. 2 ) and water (2.0 W / cm2) 2 This is a graph comparing the photothermal effect when the multifunctional particles of Manufacturing Example 1 and Comparative Example 1 are irradiated with an 808 nm continuous wave laser at a power density of .
[0041] Figure 10 is a graph showing TEM images and size distribution of multifunctional particles of Manufacturing Examples 2 to 5 of the present invention.
[0042] Figure 11 is a graph comparing the 1.0 μm emission spectra of the multifunctional particles of Manufacturing Examples 1 to 5 of the present invention, and the image is a graph showing the intensity thereof.
[0043] Figure 12 shows the 0.1 W / cm of the multifunctional particles of manufacturing example 3 of the present invention. 2 A graph comparing the 1.0 μm emission spectra in cyclohexane and water at power density.
[0044] Figure 13 shows the cyclohexane (0.5 W / cm) of the present invention. 2 ) and water (2.0 W / cm2) 2 This is a graph comparing the photothermal effect when irradiating the multifunctional particles of Comparative Example 2 and Manufacturing Example 3 with an 808 nm continuous wave laser at a power density of .
[0045] Figure 14 is a thermal image of the multifunctional particles of Manufacturing Example 1, Comparative Example 1, Manufacturing Example 3, and Comparative Example 2 of the present invention in water.
[0046] Figure 15 is a thermal image of the multifunctional particles of Manufacturing Example 1, Comparative Example 1, Manufacturing Example 3, and Comparative Example 2 of the present invention in cyclohexane.
[0047] Figure 16 is a graph showing the photothermal stability of the multifunctional particles of Manufacturing Example 3 of the present invention when irradiated with an 808 nm laser for 5 on-off cycles.
[0048] Figure 17 is an energy band diagram for the upward conversion process of the multifunctional particle of Manufacturing Example 6 of the present invention.
[0049] Figure 18 is a graph comparing the dual emission spectra of the multifunctional particles of Manufacturing Example 6 of the present invention.
[0050] Figure 19 is a graph showing the lifetime profile for the emission of light having a wavelength of 800 nm when the multifunctional particle of Manufacturing Example 6 of the present invention is irradiated with a 980 nm pulse laser.
[0051] Figure 20 is a schematic diagram of an in vitro chicken breast experiment process according to one embodiment of the present invention.
[0052] Figure 21 shows a lifespan image (left) and a conventional intensity-based image (right) according to the depth increase of chicken breast injected with multifunctional particles of Manufacturing Example 6 of the present invention.
[0053] Figure 22 is a graph showing the normalized intensity and lifetime obtained from the light emission of the multifunctional particles of Manufacturing Example 6 in Figures 20 and 21.
[0054] Figure 23 shows a chicken breast injected with multifunctional particles of Manufacturing Example 6 of the present invention using an 808 nm CW laser (1.5 W / cm 2 ), 980nm CW laser (1.5W / cm 2 ) and pulsed 980nm laser (1.5W / cm 2 ) is an extracorporeal infrared thermal image of chicken breast measured using a .
[0055] Figure 24 shows a pulsed 980 nm laser (1.0 W / cm) inside a capillary filled with multifunctional particles of Manufacturing Example 6 of the present invention. 2 ) and 808nm CW laser (1.5W / cm 2 ) are near-infrared optical images and thermal images of a 1% intralipid solution supplied to a capillary tube during investigation.
[0056] Figure 25 is a confocal microscopy image of glioma cells (U87MG) using the multifunctional particles of Manufacturing Examples 6 and 7 of the present invention.
[0057] Figure 26 is a graph quantifying cellular uptake through measurement of the mean fluorescence intensity (MFI) of the multifunctional particles of Manufacturing Examples 6 and 7 of the present invention.
[0058] Figure 27 is a graph showing the results of photothermal therapy (PTT) efficacy when the multifunctional particles of Manufacturing Examples 6 and 7 of the present invention were irradiated with laser for 5 minutes and 10 minutes, respectively.
[0059] Figure 28 is a schematic diagram of an experimental setup for evaluating laser tissue penetration and cell morphology images after treatment according to one embodiment of the present invention.
[0060] Figure 29 is a graph showing the cell viability analysis after exposing the control group (PBS), the multifunctional particles of Preparation Examples 6 and 7 to laser with or without chicken breast intervention in the experiment of Figure 28.
[0061] Figure 30 is a schematic diagram showing a photothermal treatment performed by injecting multifunctional particles according to one embodiment of the present invention into a mouse with glioblastoma (GBM).
[0062] Figure 31 is a schematic diagram showing a GBM orthotopic transplantation mouse modeling and treatment schedule according to one embodiment of the present invention.
[0063] Figure 32 is a lifespan and near-infrared (NIR) image of a mouse brain 5 minutes after injection of the multifunctional particle of Manufacturing Example 7 of the present invention into the tail vein.
[0064] Figure 33 shows in vitro life images of a rat brain 1 minute, 5 minutes, and 60 minutes after injection of the multifunctional particles of Manufacturing Example 7 of the present invention into the tail vein.
[0065] Figure 34 is a graph quantifying the multifunctional particles of Manufacturing Example 7 of the present invention accumulated in the GBM after injection into the tail vein.
[0066] Figure 35 is a thermal image of a GBM lesion in a mouse model in which the control group (PBS), multifunctional particles of Preparation Examples 6 and 7 of the present invention were injected into the tail vein and subjected to laser irradiation for 5 minutes.
[0067] Figure 36 is a graph showing the temperature increase of a GBM lesion irradiated with a laser for 120 seconds to the control group (PBS), multifunctional particles of Preparation Examples 6 and 7 of the present invention.
[0068] Figure 37 shows images of TUNEL analysis of the control group (PBS), multifunctional particles of Preparation Examples 6 and 7 of the present invention, and images of five individual brain sections using Nissl staining.
[0069] Figure 38 is a graph showing the quantification of tumor volume after photothermal therapy (PTT) using the control group (PBS), multifunctional particles of Preparation Examples 6 and 7 of the present invention.
[0070] Figure 39 is a graph quantifying the TUNEL MFI of the control group (PBS), manufacturing examples 6 and 7 of the present invention.
[0071] Figure 40 is an H&E staining image of a brain section to which the control group (PBS), Manufacturing Examples 6 and 7 of the present invention were applied.
[0072] Figure 41 is an image showing the results of immunofluorescence staining for anti-EGFR antibody (green), anti-CD133 antibody (red), and DAPI (blue) in brain sections containing GBM to which the control group (PBS) of the present invention, and the multifunctional particles of Preparation Examples 6 and 7 were applied.
[0073] Hereinafter, an embodiment of the present invention will be described in detail with reference to the attached drawings.
[0074] While the present invention is susceptible to numerous modifications and variations, specific embodiments thereof are illustrated in the drawings and will be described in detail below. However, the invention is not intended to be limited to the particular forms disclosed; rather, the invention includes all modifications, equivalents, and alternatives consistent with the spirit of the invention as defined by the claims.
[0075] When an element such as a layer, region or substrate is referred to as existing "on" another element, it will be understood that this may be directly on the other element, or that there may be intermediate elements in between.
[0076] Although the terms first, second, etc. may be used to describe various elements, components, regions, layers and / or regions, it will be understood that these elements, components, regions, layers and / or regions should not be limited by these terms.
[0077] Example
[0078] Figure 1 is a schematic diagram showing a multifunctional particle for near-infrared imaging guidance and photothermal therapy according to one embodiment of the present invention.
[0079] Referring to FIG. 1, the multifunctional particle (1) of the present invention may include a core (100) and a shell (200).
[0080] The core (100) may be positioned at the center of the multifunctional particle (1). The core (100) may absorb light having a first wavelength and emit near-infrared light having a second wavelength shorter than the first wavelength. Specifically, the core (100) may absorb light having a first wavelength irradiated to the core (100) and up-convert it to emit light having a near-infrared range having a second wavelength shorter than the first wavelength. The near-infrared light having the second wavelength emitted from the core (100) may induce near-infrared imaging. By using this, the multifunctional particle of the present invention may be used as an optical imaging probe or a bio-imaging probe.
[0081] In general, near-infrared (NIR) is light with a wavelength ranging from 780 to 1,300 nm, and is a part of the electromagnetic spectrum that is normally invisible to the naked eye. Signals composed of near-infrared light have less scattering than other signals, can penetrate deeply, have long wavelengths, and can operate even under adverse conditions. Accordingly, the present invention can effectively induce optical imaging using near-infrared light by configuring the core (100) to absorb infrared light of a first wavelength and emit near-infrared light of a second wavelength shorter than the first wavelength through upconversion.
[0082] The light having the first wavelength and the light having the third wavelength are both near-infrared, but may have different wavelength ranges. Accordingly, the core (100) and the shell (200) can each absorb light having different wavelength ranges.
[0083] Specifically, the range of the first wavelength may be 950 to 980 nm, and the range of the second wavelength may be 800 to 850 nm. More specifically, the range of the first wavelength may be 970 to 980 nm, and the range of the second wavelength may be 800 to 830 nm. Preferably, the core (100) can absorb light having a wavelength of 980 nm and emit near-infrared light having a wavelength of 800 nm. By the core (100) absorbing light having a wavelength of 980 nm, autofluorescence of intracellular biomolecules and the level of photodamage to cells can be minimized.
[0084] The light having the first wavelength may be supplied using a pulse laser. A pulse laser refers to a laser with a short pulse width, and can be distinguished from a continuous wave laser that continuously generates laser light. The present invention can minimize deformation and damage due to heat of cells or materials located in the surroundings when irradiating light having the first wavelength to the core (100) by using a pulse laser. For example, when supplying light having the first wavelength using a continuous wave laser, high temperatures may be transmitted or generated in the surrounding cells or materials, thereby increasing the level of light damage. Specifically, this can be referred to the following experimental examples and drawings.
[0085] FIG. 2 is a schematic diagram of inducing near-infrared (NIR) imaging using a pulse laser in a multifunctional particle according to one embodiment of the present invention.
[0086] As shown in Fig. 2, when the core of the multifunctional particle of the present invention is irradiated with a pulsed laser having a wavelength of 980 nm, light having a wavelength of 800 nm can be emitted. The emitted light can be detected as an imaging signal through a near-infrared imaging device.
[0087] The core (100) and the shell (200) contain the same host material, and the core (100) and the shell (200) may have dopants of different compositions. Through this, the core (100) can perform a function of inducing near-infrared imaging, and the shell can perform a photothermal therapy function.
[0088] Specifically, the host material of the core (100) may have a host lattice. The host material having the host lattice may protect the doping material from the surrounding environment and minimize self-absorption of biological materials. Specifically, the host material may include at least one selected from fluoride, oxide, halide, sulfur oxide, phosphate, and vanadate. More specifically, the host material may be a fluoride and may include, for example, at least one selected from NaYF4, NaGdF4, KGdF4, YOF, BaLaF5, LaF3, NaLuF4, and SrF2. Preferably, the host material may be NaYF4.
[0089] The above core (100) may include a material in which the host material is doped with a lanthanide dopant. The lanthanide dopant may be Yb 3+ , Tm 3+ , Ln 3+ , Er 3+ , Nd 3+ , Ln 3+ , Nd 3+ , Sm 3+ , Dy 3+ or Ho 3+ may include. Specifically, the host material of the core (100) may include Yb 3+ , Tm 3+ , Er 3+ , Eu 3+ and Pr 3+At least one dopant may be doped among them. More specifically, the core (100) includes a host material composed of NaYF4, and the host material includes Yb 3+ Wow Tm 3+ These can be doped at the same time.
[0090] More preferably, the core (100) comprises Na(a mol% Y)F4:b mol% Yb, c mol% Tm, wherein a is 100-bc, b is 40 to 60, and c may be 1 to 10. Specifically, b may be 45 to 55, and c may be 3 to 8. Even more specifically, b may be 50, and c may be 2. By configuring the core (100) in the above-described range, near-infrared imaging can be effectively induced.
[0091] As described above, by simultaneously doping tholium (Tm) with ytterbium (Yb) into the core (100), long-lived near-infrared (NIR) imaging can be induced due to the delay time resulting from upconversion. Specifically, the NIR having a second wavelength emitted from the core (100) can have a long-lived lifetime in the range of several microseconds (one millionth of a second). Accordingly, the NIR having a second wavelength emitted from the core (100) can be effectively distinguished from autofluorescence and background noise of biological molecules such as nicotinamide adenine dinucleotide (NADH), collagen, tryptophan, or melanin, which have a lifetime of several nanoseconds (one billionth of a second). Accordingly, the near-infrared ray emitted from the core (100) can be easily detected by the near-infrared imaging device, thereby increasing the accuracy of the signal. Specifically, the near-infrared ray having the second wavelength may have a lifetime in the range of 300 to 600 microseconds (μs). More specifically, the near-infrared ray having the second wavelength may have a lifetime in the range of 400 to 500 microseconds (μs). Preferably, the near-infrared ray having the second wavelength may have a lifetime in the range of 430 to 434 microseconds. More specifically, this can be seen with reference to the following experimental examples and drawings.
[0092]
[0093] Referring to FIG. 1, the shell (200) may be formed to be positioned on the outside of the core (100) and surround the core (100). The shell (200) may absorb light having a third wavelength and emit light having a fourth wavelength that induces absorption of water.
[0094] Specifically, light having a fourth wavelength emitted from the shell (200) can be converted into heat through a photothermal effect and locally heat water molecules arranged around the multifunctional particle (1). That is, the present invention may configure the shell (200) with a material that emits light having a fourth wavelength that induces absorption of water in the multifunctional particle (1) in order to minimize the distance between water molecules. Through this, the photothermal effect between the shell (200) and water molecules can be further enhanced.
[0095] In general, the photothermal effect refers to the effect of absorbing light and releasing heat, and may vary depending on the composition of the particles or the wavelength and intensity of the laser irradiated on the particles. Accordingly, the present invention can be configured to emit light having a wavelength that induces absorption of water from the shell (200) in order to locally heat water molecules. For this purpose, the range of the fourth wavelength may be 950 to 1,050 nm. The shell (200) can induce absorption of water by being configured to emit light having a wavelength within the absorption band range of water.
[0096] Additionally, the range of the third wavelength may be 780 to 808 nm. More specifically, the range of the third wavelength may be 790 to 808 nm, and the range of the fourth wavelength may be 960 to 1,030 nm. Preferably, the shell (200) may absorb light having a wavelength of 808 nm and emit light having a wavelength of 1,000 nm.
[0097] Specifically, the luminescent energy of 1000 nm (1.0 μm) emitted from the shell (200) can be non-radiatively transmitted by stretching vibrations of coordinated solvent molecules around it. Meanwhile, strong absorption of water can occur in the near-infrared (NIR) region around 1.0 μm. Specifically, since the second overtone of the stretching band of water provides significant absorption ability around the 950 to 1,050 nm region, light having a wavelength of 1000 nm emitted from the shell (200) can be strongly absorbed by water molecules. That is, the present invention can locally heat water molecules by configuring the shell (200) to emit light having a wavelength of 1,000 nm with strong energy targeting the absorption band of water. Through this, the multifunctional particle (1) of the present invention can treat (or kill) cancer cells or remove environmental pollutants such as viruses or microorganisms.
[0098] As described above, the multifunctional particle of the present invention can kill about 78% of cancer cells by directly heating water molecules, which are a major component of the body, by enhancing the photothermal effect through the shell (200). In addition, the photothermal effect by light having a wavelength of 1,000 nm emitted from the shell (200) can exhibit higher efficiency than the cross-relaxation (CR)-induced photothermal effect, which is a phenomenon that occurs between the ions themselves doped in the conventional particles or between other neighboring ions in an energy state such as a ladder, as shown in FIG. Specifically, this can be referred to the following experimental examples and drawings.
[0099] FIG. 3 is a schematic diagram showing a photothermal treatment performed through local heating of water molecules using a continuous wave laser (CW laser) on a multifunctional particle according to one embodiment of the present invention, and an energy band diagram of the multifunctional particle related thereto.
[0100] As shown in Fig. 3, when a continuous wave laser having a wavelength of 808 nm is irradiated on the shell of the multifunctional particle of the present invention, light having a wavelength of 1,000 nm can be emitted. The emitted light can locally heat water molecules arranged around the multifunctional particle, and photothermal therapy (PTT) can be performed using the heated water molecules (heated H2O).
[0101] The host material of the shell (200) may have a host lattice. The host material having the host lattice may protect the doping material from the surrounding environment and minimize self-absorption of biological materials. Specifically, the host material may include at least one selected from fluoride, oxide, halide, sulfur oxide, phosphate, and vanadate. More specifically, the host material may be a fluoride and may include at least one or more selected from NaYF4, NaGdF4, KGdF4, YOF, BaLaF5, LaF3, NaLuF4, and SrF2. Preferably, the host material of the shell (200) may be NaYF4.
[0102] The above shell (200) may include a host material doped with a lanthanide dopant. The lanthanide dopant may be Yb 3+ , Tm 3+ , Ln 3+ , Er 3+ , Nd 3+ , Ln 3+ , Nd 3+ , Sm 3+ , Dy 3+ or Ho 3+may include. Specifically, the host material of the shell (200) may include Yb 3+ , Ln 3+ , Nd 3+ , Sm 3+ , Dy 3+ and Ho 3+ At least one dopant may be doped among them. More specifically, the shell comprises a host material composed of NaYF4, and the host material comprises Yb 3+ Wow Nd 3+ These can be doped at the same time.
[0103] Preferably, the shell is Na(x mol% Y)F4:y mol% Nd, z mol% Yb, where x is 100-yz, y is 20 to 70, and z may be 10 to 30. Specifically, y may be 35 to 55, and z may be 15 to 25. More specifically, y may be 40, and z may be 20. By configuring the shell (200) within the above-described range, photothermal therapy can be effectively performed. Specifically, this can be seen with reference to the following experimental examples and drawings.
[0104] FIG. 4 is a schematic diagram showing a multifunctional particle for near-infrared imaging and photothermal therapy doped with ytterbium (Yb), tholium (Tm), and neodymium (Nd) according to one embodiment of the present invention.
[0105] As shown in Fig. 4, the multifunctional particle of the present invention has a core of Yb 3+ and Tm 3+ It consists of NaYF4 doped with Yb, and the shell is 3+ and Nd 3+ It can be composed of doped NaYF4.
[0106] As shown in FIG. 1 and FIG. 4, the multifunctional particle (1) of the present invention can reduce energy loss on the surface of the multifunctional particle (1) by forming the core (100) and the shell (200) in a core@shell structure. Specifically, the sensitizer material (for example, Nd) included in the multifunctional particle (1) 3+ ) by the core@shell structure, the activator material (e.g., Yb 3+ ) can effectively separate from the energy back-transfer.
[0107] In addition, the multifunctional particle (1) of the present invention has a neodymium ion (Nd) in the shell (200) through the core@shell structure described above. 3+ ) can be doped at a high concentration of 20 to 70 mol%, specifically 40 mol% or more, to further minimize energy inversion. This can contribute to achieving higher luminescence intensity and increased cross-relaxation (CR).
[0108]
[0109] Another aspect of the present invention can provide a method for producing the multifunctional particles described above. The method for producing the multifunctional particles can be performed using a method for thermal decomposition of lanthanide acetate. Specifically, the multifunctional particles can be prepared by mixing a solution containing a first lanthanide (e.g., yttrium (Y), ytterbium (Yb), and thorium (Tm)) with oleic acid and 1-octadecene, heating, and then cooling. This can be added to a solution of sodium hydroxide, an inorganic multifunctional particle forming reaction solution (e.g., NH4F), and methanol, mixing, heating, and then cooling to form a core. Thereafter, a solution containing a second lanthanide (e.g., yttrium (Y), neodymium (Nd), and ytterbium (Yb)) can be mixed with oleic acid and 1-octadecene, heating, and then cooling. This can be done by mixing sodium hydroxide, a reaction solution for forming inorganic multifunctional particles (e.g., NH4F), a methanol solution, and the core, heating, and then cooling to form a shell on the outside of the core. Specifically, this can be done by referring to the experimental examples and drawings below.
[0110] In addition, the multifunctional particles must be biocompatible for near-infrared imaging guidance and photothermal therapy and must bind to a specific target, so they can be formed to be dissolved in an aqueous solution. To this end, an organic ligand can be attached to the surface of the multifunctional particles, and an amphiphilic polymer that interacts with the nonpolar group of the particle surface ligand can be attached or surface silanized. Specifically, the surface treatment for utilizing the multifunctional particles can use a conventional method such as sol-gel, but is not limited thereto. The solubility of the multifunctional particles in an aqueous solution can be increased through the surface treatment of the multifunctional particles.
[0111]
[0112] Another aspect of the present invention provides a complex comprising a multifunctional particle comprising a core that absorbs light having a first wavelength and emits near-infrared light having a second wavelength shorter than the first wavelength to induce near-infrared imaging, and a shell located outside the core and that emits light having a fourth wavelength that absorbs light having a third wavelength and induces absorption of water while locally heating water molecules, and a tumor-targeting antibody attached to the surface of the multifunctional particle. That is, the complex can induce near-infrared imaging of the tumor through the multifunctional particle linked to the tumor-targeting antibody by binding to the tumor, which is a target for photothermal therapy, and simultaneously perform photothermal therapy on the tumor by locally heating water molecules positioned in and around the tumor.
[0113] Specifically, the multifunctional particle may be a maleimide-modified antibody having a maleimide moiety exposed on the surface. The tumor-targeting antibody may be a thiol-modified antibody bound to a maleimide moiety on the surface of the multifunctional particle.
[0114] The tumor-targeting antibody specifically binds to cancer cells, and the multifunctional particle can kill the cancer cells by locally heating water molecules. The cancer cells may be at least one cell selected from the group consisting of glioblastoma cells, sarcoma cells, lymphoma cells, glioma cells, breast cancer cells, head and neck cancer cells, prostate cancer cells, and lung cancer cells.
[0115] Specifically, the tumor-targeting antibody may be an antibody that specifically binds to glioblastoma cells. More specifically, the tumor-targeting antibody may be a CD133 antibody, which is a transmembrane protein. In general, brain tumors have various barriers such as the scalp, skull, or surrounding normal brain tissue, making it difficult for light to penetrate into the tissue and thus difficult to reach GBM lesions. The complex comprising the multifunctional particle of the present invention can bind the CD133 antibody to the multifunctional particle, interact with the transmembrane protein (CD133), and preferentially localize the complex to the glioblastoma cell membrane, thereby effectively killing glioblastoma cells.
[0116] Below, preferred experimental examples are presented to aid understanding of the present invention. However, the following experimental examples are provided solely to aid understanding of the present invention, and the present invention is not limited to the following experimental examples.
[0117] Preparation of cell lines, cell cultures, and animal models for experiments
[0118] The human glioblastoma cell line (U87MG; Korea Cell Line Bank, Seoul) was derived from a human brain tumor. U87MG cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (high Glucose, Welgene, Gyeongsangbuk-do, Korea) containing 10% fetal bovine serum (CELLect™, Gold, 13 US Origin) and 1% penicillin-streptomycin (Gibco, USA) under standard culture conditions of 37°C and 5% CO2.
[0119] All animals were raised under specific pathogen-free conditions and managed in accordance with the Hanyang University Institutional Animal Care and Use Committee (IACUC: 2020-0081). The maximum tumor size / burden observed in this study did not exceed the acceptable limit, thus complying with the standards approved by the Hanyang University IACUC.
[0120] Preparation of samples
[0121] Neodymium(III) acetate hydrate (99.9%), yttrium(III) acetate hydrate (99.9%), ytterbium(III) acetate hydrate (99.9%), thulium(III) acetate hydrate (99.95%), oleic acid (OA, 90%), 1-octadecene (ODE, 90%), sodium hydroxide (NaOH, ≥98%), ammonium fluoride (NH4F, ≥99.9%), ethanol (absolute), methanol (≥99.8%), cyclohexane (≥99%), tetrahydrofuran (THF, ≥99.9%), dopamine hydrochloride (≥99.9%), hydrochloric acid (HCl, 37%), dimethyl sulfoxide (DMSO, ≥99.9%), hydroxylamine hydrochloride (HH, 99%), N,N-Dimethylformamide anhydrous (DMF, ≥99.8%), nitrosyl tetrafluoroborate (NOBF4, ≥95%), and PAA solution (Mw=2000 g / mol) were purchased from Sigma-Aldrich, St. Louis, MO, USA. HEPES buffer (1 M) was purchased from Gibco. N-Succinimidyl S-acetylthioacetate (SATA), sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (sulfo-SMCC), and CD133 (prominin-1) monoclonal antibody (12-1338-42) were purchased from Thermo Fisher Scientific, Waltham, MA, USA. Amicon Ultra centrifugal filters (0.5 mL, 30K, 5K) were purchased from Millipore (Bedford, MA, USA). Anti-EGFR antibody (ab40815), goat anti-rabbit IgG-H&L Alexa Fluor 488 (ab150077), and goat anti-rabbit IgG H&L Alexa Fluor 647 (ab150079) were purchased from Abcam, UK. The DAPI mounting kit was purchased from Vector Laboratories, Inc., Burlingame, CA, USA.
[0122] Manufacturing Example 1: Synthesis of NaYF4:10% Nd, 4% Yb multifunctional particles
[0123] Yttrium (Y) acetate hydrate, neodymium (Nd) acetate hydrate, and ytterbium (Yb) acetate hydrate were mixed with oleic acid and 1-octadecene. Specifically, 7 mL of 1-octadecene, 3 mL of oleic acid, and 0.4 mmol of lanthanide (consisting of 86 mol% Y, 10 mol% Nd, and 4 mol% Yb) were mixed. The mixed solution was then heated to 150°C, maintained for 30 minutes, and then cooled to 50°C. Next, a methanol solution of NaOH (1 mM) and NH4F (1.6 mM, 5 mL) was continuously added to the oleate-lanthanide mixed solution and stirred at 50°C. After this, the obtained solution was heated to 100°C and degassed using a vacuum pump to remove residual water and methanol. Then, the resulting solution was heated to 300°C and maintained under argon (Ar) for 1 hour, and then cooled to room temperature. The precipitated multifunctional particles were collected by centrifugation and washed. The final product, NaYF4:10% Nd, 4% Yb multifunctional particles, were redispersed in cyclohexane (2 mL). The multifunctional particles of Manufacturing Example 1 are indicated as water-heating cores in the drawings and descriptions related to the drawings.
[0124] To investigate the photothermal effect in water (aqueous solution), the multifunctional particles of Preparation Example 1 were modified into water-soluble multifunctional particles through surface ligand exchange of oleic acid-capped hydrophobic multifunctional particles and dopamine hydrochloride (dopamine-coated multifunctional particles). Specifically, 15 mg of the multifunctional particles of Preparation Example 1 were dissolved in tetrahydrofuran (THF), and 50 mg of dopamine hydrochloride was dissolved in water. The solutions were mixed in a flask (50 mL) and heated to 50°C with vigorous stirring. Then, hydrochloric acid (HCl) was added, and the generated NH2-ligand was collected through several washing steps. The NH2-multifunctional particles (2 mg) were dispersed in HEPES buffer (10 mM, 200 μL). Sulfo-SMCC was dispersed in HEPES buffer (10 mM), and these solutions were mixed and incubated for 5 hours to form maleimide ligand-modified multifunctional particles.
[0125] Comparative Example 1: Synthesis of NaYF4:10% Nd multifunctional particles
[0126] Except that 0.4 mmol of lanthanide (consisting of 90 mol% Y, 10 mol% Nd) without adding ytterbium (Yb) acetate hydrate was used in the above Manufacturing Example 1, the same procedure as Manufacturing Example 1 was followed to form NaYF4:10% Nd multifunctional particles as the final product. The multifunctional particles of Comparative Example 1 are indicated as cross relaxation cores in the drawings and descriptions related to the drawings.
[0127] Experimental Example 1: Characteristics of the multifunctional particles (water-heating core) of Manufacturing Example 1
[0128] (1) Measurement of size and shape of multifunctional particles: The water-heating core of Manufacturing Example 1 had an average size of 18.5±1.7 nm and was uniformly spherical. As a result of X-ray diffraction analysis (XRD), the water-heating core of Manufacturing Example 1 was composed of pure hexagonal NaYF4 (pure hexagonal phase).
[0129] (2) Photothermal effect: In order to prove the water-heating effect of the water-heating core of Manufacturing Example 1 that emits 1.0 μm of luminescence, it was compared with the cross relaxation core of Comparative Example 1 that exhibits the photothermal effect only in the existing cross relaxation (CR) without 1.0 μm of luminescence.
[0130] FIG. 5 is a schematic diagram showing the thermal effect induced by cross relaxation (CR) of the multifunctional particles of Comparative Example 1 and the multifunctional particles of Manufacturing Example 1, and FIG. 6 is a schematic diagram showing the photothermal effect of the water-heating core of Manufacturing Example 1 of the present invention.
[0131] Referring to Figure 5, Nd in Comparative Example 1 and Manufacturing Example 1 3+ All of the doped multifunctional particles were excited at 808 nm ( 4 F 3 / 2 , 4 I 15 / 2 )and ( 4 I 15 / 2 , 4 I 9 / 2 ) states, CR-induced heat was generated by ionic interactions between the Nd 3+ Stepwise energy transfer of ions ( 4 F 3 / 2 , 4 I 15 / 2 ) ↔ ( 4 I 15 / 2 , 4 I 9 / 2) can generate heat by ionic interactions between states, and the photothermal performance is Nd 3+ can be determined by the doping concentration of CR. In addition, CR is mainly composed of Nd 3+ It may vary depending on the distance between ions. Specifically, 10% Nd 3+ The multifunctional particles of doped Preparation Example 1 and the multifunctional particles of Comparative Example 1 exhibited similar levels of photothermal performance in a cyclohexane solution. This can be attributed to the fact that the heat generation was solely due to CR.
[0132] On the other hand, referring to Figure 6, unlike Comparative Example 1, Yb is added to the water-heating core of Manufacturing Example 1. 3+ As the ions are present, it can be confirmed that it acts as a 1000 nm luminescence enhancer that heats water molecules.
[0133] Figure 7 shows the multifunctional particles of Manufacturing Example 1 of the present invention at 0.1 W / cm 2 This is a graph comparing the 1.0 μm emission spectra in each cyclohexane and aqueous solution by power density, and the image is an optical image of the multifunctional particles of Manufacturing Example 1 in cyclohexane and water, and FIG. 8 is a graph showing the near-infrared (NIR) absorbance spectra of cyclohexane and water.
[0134] As shown in Fig. 8, it can be seen that water has strong absorption around 1.0 μm. Accordingly, when examining the emission spectrum of the multifunctional particles of Manufacturing Example 1 that were water-solubilized as shown in Fig. 7, it can be confirmed that the wavelength of approximately 1.0 μm emitted from the multifunctional particles of Manufacturing Example 1 is strongly absorbed by water.
[0135] Figure 9 shows the cyclohexane (0.5 W / cm) of the present invention. 2 ) and water (2.0 W / cm2) 2 This is a graph comparing the photothermal effect when irradiated with an 808 nm continuous wave laser in Manufacturing Example 1 and Comparative Example 1, respectively, at a power density of .
[0136] Referring to Fig. 9, when irradiated with an 808 nm continuous wave laser, a temperature increase was observed in Comparative Example 1 and Manufacturing Example 1. Specifically, the photothermal performances of the multifunctional particles of Comparative Example 1 and the multifunctional particles of Manufacturing Example 1 in a cyclohexane solution were similar at 24.2°C and 21.8°C, respectively. In contrast, in water, the multifunctional particles of Manufacturing Example 1 showed a much higher temperature increase than the multifunctional particles of Comparative Example 1, at 20.9°C and 31.1°C, respectively. Through this, it can be seen that the multifunctional particles of Manufacturing Example 1 of the present invention exhibit a photothermal effect in water by heating water molecules using 1.0 μm luminescence.
[0137] However, since a temperature increase of 45°C or higher is generally required for tumor ablation by current photothermal therapy (PTT), the photothermal performance of the multifunctional particle of Manufacturing Example 1, 31.1°C, can be considered insufficient for thermal ablation of the tumor.
[0138] Accordingly, the present applicant invented a core@shell structured Nd-Yb co-doped multifunctional particle (NaYF4:Yb@NaYF4:Yb,Nd) capable of maximizing the heating effect in 1.0 μm luminescence, as shown in Manufacturing Examples 2 to 5 below.
[0139] Manufacturing Examples 2 to 5: Nd-Yb co-doped core@shell structure multifunctional particles
[0140] (1) NaYF4:50% Yb core formation
[0141] : Yttrium (Y) acetate hydrate and ytterbium (Yb) acetate hydrate were mixed with oleic acid and 1-octadecene. Specifically, 7 mL of 1-octadecene, 3 mL of oleic acid, and 0.4 mmol of lanthanide (consisting of 50 mol% Y and 50 mol% Yb) were mixed. The mixed solution was then heated to 150°C, maintained for 30 minutes, and then cooled to 50°C. Next, a methanol solution of NaOH (1 mM) and NH4F (1.6 mM, 5 mL) was added to the oleate-lanthanide mixed solution and stirred at 50°C. Thereafter, the obtained solution was heated to 100°C and degassed using a vacuum pump to remove residual water and methanol. The resulting solution was then heated to 300°C and maintained under argon (Ar) for 1 hour before cooling to room temperature. The precipitated multifunctional particles were collected by centrifugation and washed to form a NaYF4:50% Yb core.
[0142] (2) Shell formation
[0143] : Yttrium (Y) acetate hydrate, neodymium (Nd) acetate hydrate, and yttrium (Yb) acetate hydrate were mixed with oleic acid and 1-octadecene. Specifically, 7 mL of 1-octadecene, 3 mL of oleic acid, and 0.4 mmol of lanthanide (consisting of x mol% of Y, y mol% of Nd, and z mol% of Yb) were mixed. Then, the mixed solution was heated to 150°C, maintained for 30 minutes, and then cooled to 50°C. Next, a methanol solution of NaOH (1 mM) and NH4F (1.6 mM, 5 mL) and the above NaYF4:50% Yb core were added to the oleate-lanthanide mixed solution, and stirred at 50°C. After this, the obtained solution was heated to 100°C and degassed through a vacuum pump to remove residual water and methanol. Then, the resulting solution was heated to 300°C and maintained under argon (Ar) for 1 hour, and then cooled to room temperature. The precipitated multifunctional particles were collected by centrifugation and washed to form core@shell structured NaYF4:50% Yb@Nax%YF4:y% Nd, z% Yb multifunctional particles. In the drawings and the description related to the drawings, the multifunctional particles of Manufacturing Example 3 are referred to as water-heating NPs.
[0144] The molar ratios of x, y, and z were configured differently for each sample as shown in Table 1 below.
[0145] The manufactured multifunctional particles were modified into water-soluble multifunctional particles using the same method as in Manufacturing Example 1.
[0146]
[0147] Comparative Example 2: Synthesis of NaYF4:10% Nd@NaYF4:y% Nd, z% Yb multifunctional particles
[0148] In the core formation step of the above Manufacturing Example 3, except that 0.4 mmol of lanthanide (consisting of 90 mol% Y, 10 mol% Nd) without adding ytterbium (Yb) acetate hydrate was used, the same procedure as Manufacturing Example 3 was performed to form the final product, NaYF4:10% Nd@NaYF4:40% Nd, 20% Yb multifunctional particles. The multifunctional particles of the above Comparative Example 2 are referred to as Cross-relaxation NPs in the drawings and descriptions related to the drawings.
[0149] Experimental Example 2: Characterization of Nd-Yb Co-doped Core@Shell Structured Multifunctional Particles
[0150] (1) TEM and size distribution analysis
[0151] Figure 10 is a graph showing TEM images and size distributions of water-heating NPs of Manufacturing Examples 2 to 5 of the present invention. 3-TEM images of each sample were included for statistical analysis, and the results were expressed as mean ± standard deviation.
[0152] Referring to Fig. 10, most of the Nd-Yb co-doped core@shell structure multifunctional particles of Preparation Examples 2 to 5 exhibited a hexagonal structure. In addition, when examining their size distribution, Preparation Example 2 was 1.7±1.1 nm, Preparation Example 3 was 50.1±1.0 nm, Preparation Example 4 was 51.4±0.9 nm, and Preparation Example 5 was 52.2±1.2 nm. It can be confirmed that as the doping amount of neodymium (Nd) increased, the size of the multifunctional particles increased and exhibited a more distinct hexagonal structure.
[0153] (2) Luminescence spectrum analysis
[0154] Figure 11 is a graph comparing the 1.0 μm emission spectra of the water-heating core of Manufacturing Example 1 of the present invention and the water-heating NPs of Manufacturing Examples 2 to 5, and the image is a graph showing the intensity thereof.
[0155] Referring to Fig. 11, it can be confirmed that when the doping amount of neodymium (Nd) doped into the shell is 40 mol%, the intensity of the 1.0 μm emission spectrum is the highest.
[0156] Figure 12 shows the 0.1 W / cm of water-heating NP of manufacturing example 3 of the present invention. 2 A graph comparing the 1.0 μm emission spectra in cyclohexane and water at power density.
[0157] Referring to Fig. 12, it can be confirmed that the 1.0 μm emission of the water-heating NP of Preparation Example 3 leads to high absorption of 1.0 μm light by water, resulting in up to 97% reduction in 1.0 μm emission in water compared to the cyclohexane solution. This indicates that most of the light emitted from the multifunctional particle of Preparation Example 3 was absorbed by water.
[0158] (3) Photothermal effect analysis
[0159] The photothermal conversion efficiency of water-heating NP can be calculated by referring to the following equations (1) and (2).
[0160] … … Equation (1)
[0161] Here, η is the photothermal conversion efficiency, h is the heat transfer coefficient, S is the surface area of the container, △T is the temperature difference around the surroundings, I is the power density of the laser, A 808 Absorbance intensity, Q, of multifunctional particles in water when irradiated with an 808 nm continuous wave laser Dis The heat induced by solvent absorption, hS, can be evaluated by the following equation 2.
[0162] … … Equation (2)
[0163] Here, m is the mass of the solution (0.1 g), C p is the heat capacity of the solution (4.2 Jg -1 ), τ s is defined as time data for -lnθ (85.14s).
[0164] Figure 13 shows the cyclohexane (0.5 W / cm) of the present invention. 2 ) and water (2.0 W / cm2) 2 This is a graph comparing the photothermal effect when irradiated with an 808 nm continuous wave laser in Comparative Example 2 and Manufacturing Example 3 at a power density of ) . The internal images thereof are thermal images thereof. That is, Fig. 13 is the result of analyzing the temperature rise of the Nd-Yb co-doped core@shell structure multifunctional particle of Manufacturing Example 3 that heats water and the multifunctional particle of Comparative Example 1 whose temperature increased by the photothermal effect induced by cross relaxation (CR).
[0165] Referring to Fig. 13, when irradiated with an 808 nm continuous wave laser in a cyclohexane solution, the temperature of the water-heating NP of Preparation Example 3 increased to 37.5°C, and that of the cross-relaxation NP of Comparative Example 2 increased to 38.3°C. On the other hand, when irradiated with an 808 nm continuous wave laser in water, the temperature of the water-heating NP of Preparation Example 3 increased much more to 50.4°C, but that of the cross-relaxation NP of Comparative Example 2 increased to 34.6°C. This may mean that the strong light of 1.0 μm emitted from the water-heating NP of Preparation Example 3 was converted into thermal energy by strong absorption by water derived from overtones and stretching vibrations of OH oscillators of water molecules. As described above, the water-heating NP of Manufacturing Example 3 can heat water to a temperature of approximately 50°C, which is a critical temperature for photothermal therapy efficacy, and thus it can be confirmed that it can act as a sufficient photothermal agent in a biological environment rich in water.
[0166] In addition, the photothermal conversion efficiency was calculated according to the above equations (1) and (2) reported by Roper et al. △T is 30.8℃ (approximately 50.8℃-20℃), and QDis is the heat emitted from light absorbed by the quartz sample cell. Independent measurements using a quartz cuvette cell containing distilled water gave Q Dis was 25.1mW. I was 2.0Wcm -2 , A 808 is 0.15. Using these values, the photothermal conversion efficiency of the water-heating NP of Manufacturing Example 3 was calculated to be 23.3%. On the other hand, the multifunctional particle of Comparative Example 1 was calculated to be 8.2%.
[0167] Figure 14 is a thermal image of the water-heating core of Manufacturing Example 1 of the present invention, the cross-relaxation core of Comparative Example 1, the water-heating NP of Manufacturing Example 3, and the cross-relaxation NP of Comparative Example 2 in water, and Figure 15 is a thermal image of these in cyclohexane.
[0168] Referring to FIGS. 14 and 15, it can be confirmed that, except for the cross-relaxation core of Comparative Example 1, the temperature of the heat in water in FIG. 14 is generally higher than that of the cyclohexane in FIG. 15. In addition, in FIG. 14, the temperature of the heat of the cross-relaxation NP of Comparative Example 2 is higher than that of the water-heating core of Preparation Example 1, and the temperature of the heat of the water-heating NP of Preparation Example 3 is much higher than that of the cross-relaxation NP of Comparative Example 2. That is, it can be confirmed that the water-heating NP of Preparation Example 3 exhibits the highest photothermal performance in water.
[0169] Figure 16 is a graph showing the photothermal stability of the water-heating NP of Manufacturing Example 3 of the present invention when irradiated with an 808 nm laser for 5 on-off cycles.
[0170] Referring to Fig. 16, it can be confirmed that the water-heating NP of Manufacturing Example 3 exhibits considerable thermal stability even after being exposed to 808 nm continuous wave laser irradiation for several cycles.
[0171] Manufacturing Example 6: Formation of multifunctional particles for near-infrared imaging guidance and photothermal therapy.
[0172] (1) NaYF4:50% Yb, 2% Tm core formation
[0173] : Yttrium (Y) acetate hydrate, ytterbium (Yb) acetate hydrate, and tholium (Tm) acetate hydrate were mixed with oleic acid and 1-octadecene. Specifically, 7 mL of 1-octadecene, 3 mL of oleic acid, and 0.4 mmol of lanthanide (consisting of 48 mol% Y, 50 mol% Yb, and 2% Tm) were mixed. Then, the mixed solution was heated to 150°C, maintained for 30 minutes, and then cooled to 50°C. Next, a methanol solution of NaOH (1 mM) and NH4F (1.6 mM, 5 mL) was added to the oleate-lanthanide mixed solution, and stirred at 50°C. Thereafter, the obtained solution was heated to 100°C and degassed using a vacuum pump to remove residual water and methanol. The resulting solution was then heated to 300°C and maintained under argon (Ar) for 1 hour before cooling to room temperature. The precipitated multifunctional particles were collected by centrifugation and washed to form a NaYF4:50% Yb, 2% Tm core.
[0174] (2) Shell formation
[0175] : Yttrium (Y) acetate hydrate, neodymium (Nd) acetate hydrate, and yttrium (Yb) acetate hydrate were mixed with oleic acid and 1-octadecene. Specifically, 7 mL of 1-octadecene, 3 mL of oleic acid, and 0.4 mmol of lanthanide (consisting of 40 mol% Y, 40 mol% Nd, and 20 mol% Yb) were mixed. Then, the mixed solution was heated to 150°C, maintained for 30 minutes, and then cooled to 50°C. Next, a methanol solution of NaOH (1 mM) and NH4F (1.6 mM, 5 mL) and the above NaYF4:50% Yb, 2% Tm core were added to the oleate-lanthanide mixed solution, and stirred at 50°C. After this, the obtained solution was heated to 100°C and degassed using a vacuum pump to remove residual water and methanol. Then, the resulting solution was heated to 300°C and maintained under argon (Ar) for 1 hour, and then cooled to room temperature. The precipitated multifunctional particles were collected by centrifugation and washed to form core@shell structured NaYF4:50% Yb, 2% Tm@NaYF4:40% Nd, 20% Yb multifunctional particles. The above Preparation Example 6 is referred to as water-heating NIR NPs in the drawings and the description related to the drawings.
[0176] The manufactured multifunctional particles were modified into water-soluble multifunctional particles using the same method as in Manufacturing Example 1.
[0177] Experimental Example 3: Characterization of Multifunctional Particles for Near-Infrared Imaging Guidance and Photothermal Therapy
[0178] (1) Analysis of luminescence spectrum and lifetime profile
[0179] Figure 17 is an energy band diagram for the up-conversion process of water-heating NIR NP of Manufacturing Example 6 of the present invention.
[0180] Referring to Figure 17, Manufacturing Example 6 has 2% Tm in the core to have a near-infrared (NIR) emission spectrum with a wavelength of 800 nm when irradiated with a 980 nm laser in order to impart near-infrared (NIR) luminescence characteristics. 3+ Ions are doped.
[0181] Fig. 18 is a graph comparing the dual emission spectra of the water-heating NIR NP of Manufacturing Example 6 of the present invention. The left graph of Fig. 18 is an 800 nm emission spectrum for long-life near-infrared (NIR) imaging from a pulsed 980 nm laser, and the right graph is a graph showing a 1.0 μm emission spectrum for photothermal therapy (PTT) from an 808 nm continuous wave (CW) laser.
[0182] As shown in Fig. 18, when irradiated with an 800 nm pulse laser and an 808 nm continuous wave (CW) laser, it can be confirmed that two distinct emissions, specifically, 800 nm emission for near-infrared (NIR) long-life imaging and 1.0 μm luminescence for photothermal effects, are promoted, respectively.
[0183] Figure 19 is a graph showing the lifetime profile for 800 nm emission upon 980 nm pulse excitation of water-heating NIR NP of Manufacturing Example 6 of the present invention (power density is 1.0 W / cm 2 ).
[0184] As shown in Fig. 19, the lifetime profile for luminescence was obtained at a cycle of 0.1 ms using a function generator. The lifetime decay was obtained through exponential fitting for a selected region of interest (ROI) of the image, and the lifetime of the water-heating NIR NP of Preparation Example 6 in aqueous solution was calculated to be 436±3.5 μs. The lifetime was calculated by obtaining the time value from the graph obtained from Equation (3), which is the equation for single exponential decay in the profile obtained in Fig. 19.
[0185] … … Equation (3)
[0186] (2) Near-infrared lifespan analysis using chicken breast
[0187] FIG. 20 is a schematic diagram of an in vitro chicken breast experiment process according to one embodiment of the present invention, FIG. 21 is a lifetime image (left) and a conventional intensity-based image (right) according to the depth increase of chicken breast injected with water-heating NIR NPs of Manufacturing Example 6 of the present invention, and FIG. 22 is a graph showing normalized intensity and lifetime obtained from the emission of water-heating NIR NPs of Manufacturing Example 6 in FIGS. 20 and 21.
[0188] As shown in Fig. 20, a near-infrared (NIR) imaging experiment with an in vitro long-term lifetime was performed by injecting the water-heating NIR NPs of Manufacturing Example 6 of the present invention into chicken breast. Referring to Figs. 21 and 22, it can be confirmed that the NIR emission intensity of the water-heating NIR NPs of Manufacturing Example 6 decreases as the chicken breast depth increases in the range of 0 to 6 mm for traditional intensity-based imaging measurements under continuous wave (CW) laser irradiation. In contrast, the lifetime imaging derived from the decay time recognized the NIR emission against the background signal with consistent pseudocolor.
[0189] Figure 23 shows the results of a 808 nm continuous wave (CW) laser (1.5 W / cm) applied to chicken breast injected with water-heating NIR NP of Manufacturing Example 6 of the present invention. 2 ), 980 nm continuous wave (CW) laser (1.5 W / cm 2 ) and pulsed 980nm laser (1.5W / cm 2 ) is an extracorporeal infrared thermal image of chicken breast measured using a .
[0190] Referring to Figure 23, the temperature of the chicken breast was measured as a result of irradiation with a 980 nm pulse laser at a period of 0.1 ms and a power of 1.0 W / cm. 2 The power density of the 980 nm continuous wave (CW) laser increased by about 3℃. However, it can be confirmed that the temperature increased by more than 50℃ when irradiated with a 980 nm continuous wave (CW) laser, which poses a risk of overheating and unwanted thermal effects. Therefore, the overheating effect of the 980 nm pulse laser can be ignored as a source of long-life near-infrared (NIR) in vivo imaging. As described above, since the water-heating NIR NP of Preparation Example 6 of the present invention can clearly confirm luminescence against the background signal, it is judged that lifetime imaging using the multifunctional particle of the present invention is very useful and suitable for deep tissue imaging without heat increase (>3℃).
[0191] (3) Lifespan imaging and photothermal effect analysis using biological tissue (intralipid)
[0192] 1% intralipid was used as a mimic of biological tissue to confirm the clarity of lifetime imaging and localized water molecule heating in the capillary. Water-heating NIR NPs (5 mg / mL) from Preparation Example 6 were filled into one capillary. The capillary tube was then placed between other tubes containing a 1% intralipid solution.
[0193] Figure 24 shows a pulsed 980 nm laser (1.0 W / cm) inside a capillary filled with water-heating NIR NPs of Manufacturing Example 6 of the present invention. 2 ) and 808 nm continuous wave (CW) laser (1.5 W / cm 2 ) During the investigation, near-infrared optical images and thermal images are obtained in a 1% intralipid solution supplied to the capillary tube.
[0194] As shown in Figure 24, the lifetime profile was calculated to be 432±1.7 μs under 980 nm pulsed laser irradiation and 808 nm continuous wave (CW) laser irradiation. The lifetime was calculated using the same method as in Figure 19 above. The temperature increased to 55°C at a depth of 4 mm in a 1% intralipid solution.
[0195] Manufacturing Example 7: Antibody surface treatment for utilization of multifunctional particles
[0196] To prepare antibody-conjugated multifunctional particles, the multifunctional particles (15 mg) of Manufacturing Example 6 were mixed with SATA stock solution to native antibody (50 μg) for 30 minutes. HH solution (1.75 μL, 0.5 M) was continuously added thereto and incubated for 2 hours. The resulting solution was washed using a 30-k centrifugal filter to form a thiol-modified antibody. Thereafter, the thiol-modified antibody and the maleimide ligand-modified multifunctional particles were linked by a click reaction. The antibody concentration was determined by the absorption spectrum at 280 nm. Finally, the surface of the antibody-multifunctional particles was covered with a 1% BSA solution to minimize nonspecific binding. Some of the surfaces of the multifunctional particles are antibody-conjugated, and the non-antibody-conjugated portion may have surface-modifying groups for action in an aqueous solution as disclosed in Manufacturing Example 6.
[0197] The above raw antibody was used as a GBM targeting ligand, anti-CD133 mAb. Accordingly, anti-CD133 mAb was conjugated to the water-heating NIR NP of Manufacturing Example 6.
[0198] CD133 is a transmembrane protein preferentially expressed on the membrane of GBM cells, and the interaction between anti-CD133 mAb and CD133 can induce endocytosis, making it an ideal target for delivering water-heating NIR NPs to improve GBM treatment.
[0199] Specifically, CD133 has been reported to be a necessary factor for GBM cells to adapt to conventional treatments (radiation and chemotherapy), migrate between different clonal populations in the tumor, and reappear to initiate tumor relapse. Recent clinical and translational studies have shown that targeting CD133 with anti-CD133 antibodies significantly improved the efficacy of immunotherapy in patient-derived GBM models. Therefore, anti-CD133 antibodies have been utilized to treat GBM.
[0200] Experimental Example 4: Analysis of water-heating NIR NPs conjugated with target ligands
[0201] In the drawings and descriptions of the drawings, Ab-NP (water-heating NIR NP conjugated with anti-CD133 mAb, Manufacturing Example 7) and bare-NP (water-heating NIR NP not conjugated with anti-CD133 mAb, Manufacturing Example 6) were indicated. To investigate the stability, Ab-NP was dispersed in 1 mM PBS (phosphate buffered saline) and 10% FBS (fetal bovine serum) solution, stored at 4°C, and changes in luminescence intensity and polydispersity index (PDI) were monitored by dynamic light scattering.
[0202] Cell culture and MTT assay
[0203] U87MG cells were cultured in T-75 cell culture plates containing DMEM (10 mL) containing 10% FBS and 1% penicillin-streptomycin in a cell incubator under environmental conditions of 5% CO2 and 37°C. When the cells reached more than 70% confluency, they were washed twice with DPBS, treated with Trypsin-EDTA (3 mL), and then incubated in a humidified atmosphere at 37°C to detach the cells. After collecting the cells by centrifugation, the cells (10 μL) were mixed with trypan blue (10 μL), and the cell number was counted using a hemocytometer. The cells were then diluted with culture medium to the concentration required for each experiment. The cytotoxicity of the NPs was evaluated by calculating the cell viability using the MTT assay. U87MG cells were seeded at 1 × 10 per well in a 96-well plate. 4 The cells were inoculated at a density of 24 h.
[0204] Cells were treated with 0, 25, 50, 100, 200, and 400 μg mL, respectively. -1 The multifunctional particles of Example 7 were treated at various concentrations. After reacting for 24 and 72 hours in a dark room without light, MTT reagent (100 μL, 0.5 mg mL -1 ) was added to each well and incubated for an additional 4 hours. Afterwards, excess MTT solution was removed from each well, and the formed formazan was dissolved in DMSO (100 μL). The absorbance of the MTT product was acquired at 570 nm using a Varioskan Flash spectral scanning multimode reader (Thermo Fisher Scientific Inc., USA). Cell viability for each concentration was evaluated in triplicate and determined by comparison with untreated control cells.
[0205] The following formula was used to calculate the survival rate of cell growth.
[0206] Cell viability (%) = (absorbance value of treatment group - blank) / (absorbance value of control group - blank) x 100%
[0207] The concentration- and dose-dependent PTT effects of Preparation Example 7 (Ab-NP) on cell viability were investigated. U87MG cells were cultured in 96-well plates with various concentrations of Preparation Example 7 (Ab-NP) (0, 50, 100, 200, 400, and 800 μg mL -1 ) were cultured, and the cells were washed three times with PBS to remove excess NPs. Next, the cells were exposed to 808 nm irradiation for 0, 10, 20, and 30 min, respectively. The control group was water-heating NIR NPs with the same NIR exposure duration and loading concentration. Finally, after an additional 24 h of incubation in the dark, cell viability was measured using the MTT assay.
[0208] Flow cytometry analysis
[0209] To monitor the effect of cytotoxicity, analysis was performed using a flow cytometer (FACS Canto, BD Biosciences). U87MG cells were cultured in a 24-well microplate at 37°C for 24 h and treated with Preparation Example 7 (Ab-NP) (200 μg ml -1) were treated. After removing excess NP, the cells were subjected to NIR irradiation for 0, 10, and 20 min, followed by the addition of Sytox-Green. Prior to FACS analysis, cells cultured in microplates were detached from the wells using trypsin-EDTA and centrifuged at 1000 g for 3 min. Cells were filtered through a 100 μm cell strainer and resuspended in 1X DPBS (200 μL) containing 5% FBS. 10,000 to 20,000 events were collected using a forward scatter threshold of 10,000. Data for pulse height, area, and width parameters in each channel were collected. SG collected data using a 488 nm laser and a 530 nm bandpass filter. Flow cytometry data were then analyzed in histogram analysis using FlowJo software (version 10.8.1., FlowJo, LLC) and plotted in FCS format.
[0210] Histological study of a mouse model with orthotopic GBM
[0211] After fixation in paraformaldehyde (4%) for 2 days, the tissue samples were placed in a Leica TP1020 semi-hermetic benchtop tissue processor (Wetzlar, Germany) for washing, dehydration, clearing, and paraffin infiltration, and then embedded in blocks in paraffin. The blocks were sectioned transversely at 6 μm thickness using a Leica RM2145 Microtome (Wetzlar, Germany).
[0212] For Nissl staining, brain slides were stained with a staining solution prepared by dissolving cresyl violet acetate (0.2 g) in distilled water (150 mL) and a buffer containing acetic acid (0.1 M) and sodium acetate (0.1 M). H&E staining was performed according to the manufacturer's instructions. For immunofluorescence staining, GBM tissue slides were stained with anti-EGFR and anti-CD133 antibodies, diluted 1:100 in a mixture of phosphate-buffered saline, Tween-20 (PBST), and goat serum. Next, goat anti-rabbit IgG-H&L Alexa Fluor 488 and goat anti-rabbit IgG H&L Alexa Fluor 647 were used as secondary antibodies, followed by DAPI mounting.
[0213] Biochemistry and hematology tests
[0214] For the experiment, 24 7-week-old male BALB / c normal mice were procured from Nara Bio Co., Ltd., Korea. The control group (PBS), bare-NPs of Preparation Example 6, and Ab-NPs of Preparation Example 7 were administered intravenously three times over a period of one week to the male BALB / c normal mice. Blood was collected by cardiac puncture, and serum (100 μL, for biochemical tests) and plasma (200 μL, for complete blood count (CBC) tests) were obtained. The samples were submitted to Daegun Healthcare (DK Korea, Seoul, Korea) for complete blood count (CBC) (n=4) and biochemical tests (n=4).
[0215] Confocal microscopy and quantitative analysis
[0216] Cellular uptake between bare NPs and Ab-NPs was compared using confocal microscopy and quantitative analysis. To rule out diffusion-dependent drug uptake, in vitro experiments were conducted for a short period of time, as long incubation periods could potentially lead to passive diffusion.
[0217] Figure 25 is a confocal microscopy image of the multifunctional particles of Manufacturing Example 6 (bare-NP) and Manufacturing Example 7 (Ab-NP) of the present invention for glioma cells (U87MG) (scale bar: 100 μm), and Figure 26 is a graph quantifying the cellular uptake of the multifunctional particles of Manufacturing Example 6 and Manufacturing Example 7 of the present invention through measurement of the mean fluorescence intensity (MFI). Here, the data are expressed as the mean ± SEM (n = 3 biological independent cells), and the two-sided P value is calculated by Student's t-tests.
[0218] Referring to Figures 25 and 26, the intracellular near-infrared (NIR) signal of Ab-NPs was significantly increased compared to bare-NPs even during a short drug incubation time of approximately 10 minutes. Consistent with the intracellular NIR signal images, the amounts of cellular uptakes were 132±5.1 and 195±11.0 for bare-NPs and Ab-NPs, respectively. The increased cellular uptake by conjugating anti-CD133 mAb to water-heating NIR NPs may further enhance phototoxicity upon laser irradiation.
[0219] Figure 27 is a graph showing the results of photothermal therapy (PTT) efficacy when bare-NP of Manufacturing Example 6 and Ab-NP of Manufacturing Example 7 of the present invention were used after irradiating with laser for 5 and 10 minutes. At this time, the data is expressed as the mean ± SEM (n=3) (*P<0.05, **P<0.01, ***P<0.001).
[0220] Referring to Figure 27, the dead cell population of the Ab-NP of Preparation Example 7 was 18.4% and 47.7% after 5 and 10 minutes of laser irradiation, respectively, whereas the dead cell population of the bare-NP of Preparation Example 6 did not increase even after 10 minutes of laser irradiation. This can be seen as indicating the importance of intracellular drug accumulation for exhibiting sufficient photothermal therapy (PTT) effects in GBM.
[0221] Figure 28 is a schematic diagram of an experimental setup for evaluating laser tissue penetration and cell morphology images after treatment according to one embodiment of the present invention (scale bar: 25 μm).
[0222] Laser tissue penetration can also be considered a critical issue for satisfactory photothermal therapy (PTT) in GBM. Therefore, as shown in Fig. 28, to investigate laser tissue penetration through the Ab-NPs of Preparation Example 7, the viability of cells exposed to the laser was analyzed depending on whether approximately 1 cm thick chicken breast was intervened. As a result of the analysis, as shown in the lower image of Fig. 28, morphological examination revealed no significant cell damage in both the bare-NP and Ab-NP groups treated with chicken breast intervention and without laser exposure. In contrast, the group treated with laser showed cell destruction, including membrane rupture and numerous intracellular bubbles. This can be interpreted as evidence of hyperthermia through PTT33.
[0223] Figure 29 is a graph showing cell viability analysis after exposure to laser, depending on the presence or absence of chicken breast intervention of Figure 28 of the present invention. In this case, bare-NP and Ab-NP were used at a concentration of 800 μg / mL per well. Data are expressed as mean ± SEM (n = 4 biologically independent cells). Two-sided P values were calculated using Student's t-test.
[0224] Referring to Figure 29, cell viability was observed in both bare-NP and Ab-NP regardless of the presence or absence of chicken breast interference. Specifically, consistent with the morphological study, cell viability was almost the same in both the presence and absence of chicken breast intervention. This was achieved under continuous wave (CW) laser photons (808 nm, 2.5 W / cm 2 ) can penetrate 100% through 1 cm thick tissue and sufficiently induce photothermal therapy (PTT).
[0225] More specifically, to determine the correlation between laser penetration energy density and heat generation according to the depth of chicken breast, each index was measured for chicken breasts ranging from 0 to 15 mm in thickness. The measurement results showed that the power density with interference of 10 mm chicken breast was 2.5 to 1.5 W / cm 2 Although the temperature gradually decreased, the fever was maintained at 43℃. This can be seen as indicating equivalent cell viability results regardless of chicken breast interference.
[0226] Long-term imaging and PTT effect analysis in a GBM-containing orthotopic transplantation mouse model
[0227] Figure 30 is a schematic diagram showing a photothermal treatment performed by injecting multifunctional particles according to one embodiment of the present invention into a mouse with glioblastoma (GBM).
[0228] As shown in Figure 30, to prepare an orthotopic GBM-bearing mouse model, GBM cells (U87MG cells) were injected intracranially into purchased 7-week-old male Balb / c nude mice (n=15). In detail, male nude mice (Nara Bio Company, Seoul) were anesthetized with isoflurane (3%) and fixed with ear bars in a stereotaxic apparatus (Stoelting Co., IL, USA). After anesthetizing each mouse, the scalp at the surgical site was removed, and a small hole was made under sterile conditions 2 mm lateral and 2 mm posterior to the right from the bregma. PBS (containing 1 × 106 U87MG cells, 8 μL) was placed in a 26-G Hamilton syringe (Hamilton Company, NV, USA) and the syringe was placed in the stereotaxic apparatus. After positioning the syringe needle at a depth of 3 mm, 1 μL min was injected into the cells. -1 After injection at a constant rate, a 3-minute wait was made to prevent overflow. After injection, the hole was sealed with bone wax, and the scalp was sutured. The mice were then kept for 3 weeks until the injected cells reached an appropriate size for GBM tissue. In vivo experiments were conducted 2 weeks after surgery.
[0229] Figure 31 is a schematic diagram showing a GBM orthotopic transplantation mouse modeling and treatment schedule according to one embodiment of the present invention.
[0230] As shown in Fig. 31, to investigate the near-infrared (NIR) long-term imaging and photothermal therapy (PTT) effects of Ab-NP of Preparation Example 7 in a GBM animal model, U87MG was injected into BALB / c nude mice and an orthotopic GBM model was constructed. Two weeks after GBM modeling, PBS was administered to the mice as a control group via tail vein injection, and bare-NP of Preparation Example 6 and Ab-NP of Preparation Example 7 were administered, respectively. The drug concentration was 5 mg / kg, and the laser intensity was 1.5 W / cm. 2was set to . Five minutes after drug administration, the GBM lesion was irradiated with a laser for photothermal therapy (PTT) for an additional 5 minutes. This treatment cycle was repeated three times over a period of one week.
[0231] Figure 32 is a lifespan and near-infrared (NIR) image of a rat brain for 5 minutes after tail vein injection of Ab-NP of Manufacturing Example 7 of the present invention.
[0232] As shown in Figure 32, in the first treatment, a 980 nm pulsed laser was used to monitor the lifetime of GBM lesions. Monitoring was performed using near-infrared (NIR) long-life imaging rather than NIR intensity-based imaging.
[0233] Figure 33 shows in vitro life images of a rat brain 1, 5, and 60 minutes after tail vein injection of Ab-NP of Manufacturing Example 7 of the present invention.
[0234] Figure 33 compares the GBM targeting of Ab-NPs. The accumulation and clearance profiles of bare-NPs and Ab-NPs administered within GBM tissues were monitored for 60 minutes. As a result, the near-infrared luminescence signal of Ab-NPs within GBM tissues was maximized at 5 minutes (average intensity 28.6 au) and maintained for 60 minutes (average intensity 10.8 au). This can be seen as a result of sufficient accumulation of Ab-NPs in GBM tissues. However, bare-NPs were monitored for the same period (average intensity 6.0 au at 5 minutes), and no signal was detected at 60 minutes. Note that "au" stands for animal unit.
[0235] Figure 34 is a graph showing the quantification of bare-NP and Ab-NP accumulated in GBM after tail vein injection of Ab-NP of Manufacturing Example 7 of the present invention. Data are expressed as mean ± SEM (n = 3 biologically independent animals), and two-sided P values were calculated using Student's t-test.
[0236] Referring to Figure 34, the amount of intravenously injected multifunctional particles (NPs) in GBM, quantified by inductively coupled plasma mass spectrometry (ICP-MS), was 2.4-fold and 1.9-fold higher in Ab-NPs than in NPs exposed at 1 and 5 minutes, respectively. Enhanced permeability and retention (EPR) can be considered a common phenomenon in GBM caused by abnormal angiogenesis and tumor pressure. The accumulation of bare-NPs in GBM tissue (~707.9 ppb after 5 minutes of intravenous injection) can be attributed to the EPR effect. This can be caused by a combination of increased extravasation (enhanced permeability) and decreased drainage by the lymphatic system (increased retention). However, Ab-NPs showed a marked accumulation of approximately 1370.0 ppb after 5 minutes of intravenous injection. This is thought to be due to the interaction with CD133 expressed on GBM.
[0237] Figure 35 is a thermal image of a GBM lesion by laser irradiation for 5 minutes in a rat model administered with the control group (PBS), Preparation Example 6 (bare-NP), and Preparation Example 7 (Ab-NP) of the present invention by tail vein injection, and Figure 36 is a graph showing the temperature increase of a GBM lesion by laser irradiation for 120 seconds in the control group (PBS), Preparation Example 6 (bare-NP), and Preparation Example 7 (Ab-NP) of the present invention. Data are expressed as mean ± SEM (n = 3 biologically independent animals).
[0238] Referring to Figures 35 and 36, the temperature of the GBM lesion under laser irradiation was approximately 10℃ higher than that of the bare-NP treatment due to the enhanced GBM targeting of Ab-NP. Since the Ab-NP treatment was repeated three times, the tumor volume was reduced by 59.4±3.6% and 78.9±4.5%, respectively, compared to the bare-NP treatment group and the control group.
[0239] Figure 37 shows images of TUNEL analysis of the control group (PBS), Preparation Example 6 (bare-NP), and Preparation Example 7 (Ab-NP) of the present invention, and images of five individual brain sections using Nissl staining, and Figure 38 is a graph showing the quantification of tumor volume after photothermal therapy (PTT) using the control group (PBS), Preparation Example 6 (bare-NP), and Preparation Example 7 (Ab-NP) of the present invention. The white dotted line in Figure 37 indicates the tumor site. Data are expressed as mean ± SEM (n = 5 biologically independent animals), and the two-sided P value was calculated using Student's t-test.
[0240] Referring to Figures 37 and 38, most tumor masses were significantly eliminated in five individual mice treated with Ab-NP.
[0241] TUNEL assays are typically used to identify apoptosis by labeling the blunt ends of double-stranded DNA fragments with deoxynucleotidyl transferase (TdT). Therefore, it is believed that TUNEL-positive signals should not be observed in GBM areas, as the tumor's anti-apoptotic pathways are abnormally activated, allowing cancer cells to resist apoptosis. This suggests that TUNEL staining, as expected, identifies free 3'-hydroxyl ends regardless of the chemical mechanism developed, and also stains non-apoptotic cells, such as necrotic degenerative cells. Therefore, morphological examination is necessary simultaneously with TUNEL analysis to distinguish between apoptotic and necrotic cells.
[0242] As shown in Figure 37, TUNEL-positive cells were predominantly found in the innermost GBM region, where a large area of necrotic tumor cells was observed in Nissl staining. Therefore, it is believed that TUNEL-positive cells may be necrotic tumor cells that contribute to the growth and aggressiveness of GBM.
[0243] Figure 39 is a graph showing the quantification of TUNEL MFI of the control group (PBS), Preparation Example 6 (bare-NP), and Preparation Example 7 (Ab-NP) of the present invention. Data are expressed as mean ± SEM (n = 5 biologically independent animals), and two-sided P values were calculated using Student's t-test.
[0244] Referring to Figure 39, it can be confirmed that the mean fluorescence intensity (MFI) of the control group was measured as 29.4±11.6, while the Ab-NP treatment group decreased to 3.2±2.1.
[0245] Figure 40 shows H&E staining images of the control group (PBS), Preparation Example 6 (bare-NP), and Preparation Example 7 (Ab-NP) of the present invention. Yellow dotted lines indicate thrombosis and bleeding. The results represent three independent experiments, and the scale bar is 50 μm.
[0246] Referring to Figure 40, there was no obvious damage to the normal brain tissue surrounding the GBM area, and rather, a strong PTT-induced response, such as hemorrhage and thrombosis, was observed at the tumor site. That is, hemorrhage and thrombosis at the tumor site due to PTT were mostly observed in the Ab-NPs-treated group and not in the control group. These results are consistent with the results obtained at 1.5 W / cm 2 We were able to demonstrate that the laser intensity sufficiently stimulates PTT while avoiding laser-induced side effects on normal brain tissue. However, to evaluate the effectiveness of the 808 nm laser, further optimization of the laser intensity and irradiation time is needed to precisely modulate the photothermal effect.
[0247] Figure 41 is an image showing the results of immunofluorescence staining for anti-EGFR antibody (green), anti-CD133 antibody (red), and DAPI (blue) in GBM-containing brain sections treated with the control group (PBS), Preparation Example 6 (bare-NP), and Preparation Example 7 (Ab-NP) of the present invention. The results are representative of three independent experiments, and the scale bar is 5 μm.
[0248] In general, the epidermal growth factor receptor (EGFR) is associated with a malignant phenotype distinct from low-grade brain tumors and is found in over 50% of GBMs. CD133, a cancer stem cell marker, is colocalized with EGFR, and increased phosphorylation and stability of EGFR are known to contribute to the acquisition of stem cell-like characteristics that contribute to the progression to more malignant GBMs. As shown in Figure 41, the fluorescence signals of EGFR and CD133 in GBM tissues were examined to determine the severity of tumor progression and the efficacy of CD133 targeting, respectively.
[0249] Referring to Figure 41, the fluorescent signals of EGFR and CD133 were most abundant in the control group, and these signals were mostly located in the same location in the merged image. Thus, a correlation between EGFR and CD133 in the progression of GBM to malignancy was demonstrated.
[0250] Additionally, in the bare-NP treatment group, the distribution rate of EGFR was slightly reduced compared to the control group, but the fluorescence signal of CD133 and colocalization between EGFR and CD133 were continuously detected.
[0251] Furthermore, the fluorescence signal and colocalization of CD133 were no longer detected in the Ab-NP-treated group. This supports the idea that Ab-NP targets CD133, which is expressed in GBM. Specifically, this could be because CD133, upon binding to the ligand, undergoes endocytosis and is no longer expressed on the outer membrane, allowing it to be stained by the antibody. Furthermore, the fluorescence signal of EGFR in the Ab-NP-treated group decreased compared to the other treatment groups.
[0252] Above, the present invention has been described in detail with reference to preferred embodiments, but the present invention is not limited to the above embodiments, and various modifications and changes can be made by those skilled in the art within the technical spirit and scope of the present invention.
Claims
1. A core that absorbs light having a first wavelength and emits near-infrared light having a second wavelength shorter than the first wavelength, thereby inducing near-infrared imaging; and A multifunctional particle comprising a shell located outside the core, which locally heats water molecules while absorbing light having a third wavelength and emitting light having a fourth wavelength that induces absorption of water.
2. In paragraph 1, The light having the first wavelength and the light having the third wavelength are both near-infrared. Multifunctional particles with different wavelength ranges.
3. In paragraph 1, The range of the first wavelength is 950 to 980 nm, A multifunctional particle having a second wavelength range of 800 to 850 nm.
4. In paragraph 1, A multifunctional particle having a fourth wavelength range of 950 to 1,050 nm.
5. In paragraph 1, A multifunctional particle having a third wavelength range of 780 to 808 nm.
6. In paragraph 1, A multifunctional particle, wherein light having the first wavelength is supplied using a pulse laser.
7. In paragraph 1, A multifunctional particle having a near-infrared ray having the second wavelength and a lifetime in the range of 300 to 600 microseconds (μs).
8. In paragraph 1, The core and the shell comprise the same host material, A multifunctional particle wherein the core and the shell have dopants of different compositions.
9. In paragraph 1, The core comprises at least one host material selected from the group consisting of NaYF4, NaGdF4, KGdF4, YOF, BaLaF5, LaF3, NaLuF4, and SrF2, The above host material contains Yb 3+ , Tm 3+ , Er 3+ , Eu 3+ and Pr 3+ A multifunctional particle doped with at least one dopant.
10. In paragraph 9, The above core comprises a host material composed of NaYF4, The above host material contains Yb 3+ Wow Tm 3+ These simultaneously doped, multifunctional particles.
11. In paragraph 10, The above core comprises Na(a mol% Y)F4:b mol% Yb, c mol% Tm, A multifunctional particle wherein a is 100-bc, b is 40 to 60, and c is 1 to 10.
12. In paragraph 1, The above shell comprises at least one host material selected from the group consisting of NaYF4, NaGdF4, KGdF4, YOF, BaLaF5, LaF3, NaLuF4, and SrF2, The above host material contains Yb 3+ , Ln 3+ , Nd 3+ , Sm 3+ , Dy 3+ and Ho 3+ A multifunctional particle doped with at least one dopant.
13. In paragraph 12, The above shell comprises a host material composed of NaYF4, The above host material contains Yb 3+ Wow Nd 3+ These simultaneously doped, multifunctional particles.
14. In paragraph 13, The above shell contains Na(x mol% Y)F4:y mol% Nd, z mol% Yb, A multifunctional particle wherein x is 100-yz, y is 20 to 70, and z is 10 to 30.
15. In paragraph 1, A multifunctional particle having a photothermal conversion efficiency of 8 to 23%.
16. A multifunctional particle comprising a core that absorbs light having a first wavelength and emits near-infrared light having a second wavelength shorter than the first wavelength, thereby inducing near-infrared imaging, and a shell located outside the core that locally heats water molecules while emitting light having a fourth wavelength that absorbs light having a third wavelength and induces absorption of water; A complex comprising a tumor-targeting antibody attached to the surface of the above multifunctional particle.
17. In paragraph 10, The above tumor-targeting antibody specifically binds to cancer cells, The above multifunctional particles are complexes that kill cancer cells by locally heating water molecules.
18. In paragraph 11, The above cancer cells are a complex comprising at least one cell selected from glioblastoma cells, sarcoma cells, lymphoma cells, glioma cells, breast cancer cells, head and neck cancer cells, prostate cancer cells, and lung cancer cells.
Citation Information
Patent Citations
Tumor-therapy composite nano material and preparation method thereof
CN103893128A
Composition for multiple detection of three viruses and viroid infecting Diospyros kaki and its use
KR1020230041366A
Inundation prevention system of public zone
KR102331454B1
Single NIR irradiation triggered upconversion NANO system for synergistic photodynamic and photothermal cancer therapy
US20220160892A1
Cited By
Bimodal immunochromatography test strip and application thereof
CN120254248A
A dual-mode immunochromatographic test strip and its application
CN120254248B
